Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $5.3 million.

  • Intellia Therapeutics' Gains from Investment Securities fell 376.63% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 376.63%. This contributed to the annual value of $5.4 million for FY2024, which is 84.65% down from last year.
  • Latest data reveals that Intellia Therapeutics reported Gains from Investment Securities of $5.3 million as of Q3 2025, which was down 376.63% from $5.4 million recorded in Q2 2025.
  • Intellia Therapeutics' Gains from Investment Securities' 5-year high stood at $109.7 million during Q4 2024, with a 5-year trough of $100000.0 in Q1 2023.
  • In the last 5 years, Intellia Therapeutics' Gains from Investment Securities had a median value of $5.9 million in 2025 and averaged $15.7 million.
  • Per our database at Business Quant, Intellia Therapeutics' Gains from Investment Securities skyrocketed by 1816666.67% in 2021 and then crashed by 9831.63% in 2023.
  • Intellia Therapeutics' Gains from Investment Securities (Quarter) stood at $6.2 million in 2021, then soared by 307.31% to $25.3 million in 2022, then crashed by 95.2% to $1.2 million in 2023, then skyrocketed by 8960.36% to $109.7 million in 2024, then tumbled by 95.19% to $5.3 million in 2025.
  • Its last three reported values are $5.3 million in Q3 2025, $5.4 million for Q2 2025, and $5.9 million during Q1 2025.